

DILSAN PHARMA IMPEX PRIVATE LIMITED

F-103, SATVA PRIME, B/H CHHANI SUBSTATION, NR. ATLANTIS VILLA, CHANNI, VADODARA, GUJARAT, 391740.
GSTIN NO. :- 24AAGCD9194D1ZK

DISCLOSURES UNDER REGULATION 29(1) OF SEBI (SUBSTANTIAL ACQUISITION OF SHARES AND TAKEOVERS) REGULATIONS, 2011

Part-A- Details of the Acquisition

| | | | |
|--|---|--|--|
| Name of the Target Company (TC) | REKVINA LABORATORIES LIMITED | | |
| Name(s) of the acquirer and Persons Acting in Concert (PAC) with the acquirer | M/s DILSAN PHARMA IMPEX PRIVATE LIMITED | | |
| Whether the acquirer belongs to Promoter/Promoter group | NA | | |
| Name(s) of the Stock Exchange(s) where the shares of TC are Listed | BSE Limited | | |
| Details of the acquisition as follows | Number | % w.r.t. total share/voting capital wherever applicable(*) | % w.r.t. total diluted share/voting capital of the TC (**) |
| Before the acquisition under consideration, holding of acquirer along with PACs of: | | | |
| a) Shares carrying voting rights | — | — | — |
| b) Shares in the nature of encumbrance (pledge/ lien/non-disposal undertaking/ others) | — | — | — |
| c) Voting rights (VR) otherwise than by equity shares | — | — | — |
| d) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) | — | — | — |
| e) Total (a+b+c+d) | — | — | — |

DILSAN PHARMA IMPEX PRIVATE LIMITED

F-103, SATVA PRIME, B/H CHHANI SUBSTATION, NR. ATLANTIS VILLA, CHANNI, VADODARA, GUJARAT, 391740.
GSTIN NO. :- 24AAGCD9194D1ZK

| | | | |
|--|--|-------|-------|
| Details of acquisition | | | |
| a) Shares carrying voting rights acquired | 3,85,773 | 6.40% | 6.40% |
| b) VRs acquired otherwise than by equity shares | — | — | — |
| c) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) acquired | — | — | — |
| d) Shares in the nature of encumbrance (pledge/ lien/non-disposal undertaking/ others) | — | — | — |
| e) Total (a+b+c+/-d) | 3,85,773 | 6.40% | 6.40% |
| Mode of acquisition (e.g. open market / public issue / rights issue / preferential allotment / inter-se transfer/encumbrance, etc.) | Open Market | | |
| Salient features of the securities acquired including time till redemption, ratio at which it can be converted into equity shares, etc. | Not Applicable | | |
| Date of acquisition of/date of receipt of intimation of allotment of shares / VR/ warrants/convertible securities/any other instrument that entitles the acquirer to receive shares in the TC. | 13-Jan-2025 (1,75,008 Eq. Share) 27-Jan-2025 (10,765 Eq. Share) 10-Feb-2025 (50,000 Eq. Share) 17-Feb-2025 (1,00,000 Eq. Share) 19-Feb-2025 (50,000 Eq. Share) | | |
| Equity share capital / total voting capital of the TC before the said acquisition | — | | |
| Equity share capital/ total voting capital of the TC after the said acquisition | 3,85,773 Equity Share | | |

DILSAN PHARMA IMPEX PRIVATE LIMITED

F-103, SATVA PRIME, B/H CHHANI SUBSTATION, NR. ATLANTIS VILLA, CHANNI, VADODARA, GUJARAT, 391740.
GSTIN NO. :- 24AAGCD9194D1ZK

| | |
|---|-----------------------|
| Total diluted share/voting capital of the TC after the said acquisition | 3,85,773 Equity Share |
|---|-----------------------|

Signature of the acquirer / Authorised Signatory

Place: Vadodara

Date: 20/02/2025

Note:

(*) Total share capital/ voting capital to be taken as per the latest filing done by the company to the Stock Exchange under Clause 35 of the listing Agreement.

(**) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.

(***) Part-B shall be disclosed to the Stock Exchanges but shall not be disseminated.